key: cord-0940347-kkrtqdon authors: Greinacher, Andreas; Langer, Florian; Makris, Mike; Pai, Menaka; Pavord, Sue; Tran, Huyen; Warkentin, Theodore E. title: Vaccine‐induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources date: 2021-11-10 journal: J Thromb Haemost DOI: 10.1111/jth.15572 sha: 7ff0564969a490cffd15223cb5bbc43a8d4ebf9e doc_id: 940347 cord_uid: kkrtqdon Vaccine‐induced immune thrombotic thrombocytopenia (VITT) is a rare but severe immunological reaction to the non‐replicable adenoviral vector‐based COVID‐19 vaccines. Extreme activation of platelets and the coagulation system leads to a high risk of death from venous or arterial thrombosis or secondary hemorrhage. Public and clinician awareness has reduced mortality of VITT by nearly 90%. The World Health Organization provided a guideline in July 2021 on diagnosis and management of VITT (also called thrombosis with thrombocytopenia syndrome, or TTS). Since July 2021, new, clinically relevant information has become available. This update has been summarized by the authors in an informal process with recommendations for low resource environments. We provide new available evidence on VITT to empower clinicians to recognize VITT early, then effectively diagnose and treat the disorder to reduce morbidity and mortality. We strongly encourage production of clear management pathways for primary care settings and hospital settings. Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but severe immunological reaction to the non-replicable adenoviral vector-based COVID-19 vaccines. Extreme activation of platelets and the coagulation system leads to a high risk of death from venous or arterial thrombosis or secondary hemorrhage. Public and clinician awareness has reduced mortality of VITT from about 50%, in the first case series reported in April 2021 to 22% by June 2021 in the UK and more recently to about 5% observed in Australia, where the vaccination campaign was accompanied by a widespread educational program on VITT (https://www.tga.gov.au/perio dic/ covid -19-vacci ne-weekl y-safet y-repor t-23- . This indicates that education of the public and health-care workers can substantially lower the burden of the adverse vaccination effect and may support acceptance of the vaccination campaign. The planned rollout of at least 1 billion doses of the ChAdOx1 COVID-19 vaccine (AstraZeneca) starting in October 2021 to low-and middle-income countries requires urgent availability of educational material. The World Health Organization (WHO) has developed a comprehensive document guiding diagnosis and management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease ; interim guidance 19 July 2021 (https://apps.who.int/iris/bitst ream/handl e/10665/ 34299 9/ WHO-2019-nCoV-TTS-2021.1-eng.pdf). However, since its publication in July, additional new information that is relevant for patient management has become available. To bridge the time required for updating the WHO guidelines, international authors summarized the most up-to-date information in October 2021. The summary was then reviewed by three experts in the field. We distinguish VITT, which is a unique and specific syndrome, from TTS, which may occur in other disorders such as heparininduced thrombocytopenia (HIT), severe antiphospholipid syndrome (APS), cancer-associated disseminated intravascular coagulopathy, and thrombotic thrombocytopenic purpura (TTP). VITT most commonly presents with cerebral venous sinus thrombosis, but splanchnic vein thrombosis, deep vein thrombosis and pulmonary embolism (venous thromboembolism [VTE]), and arterial thrombosis are also common, as is involvement of multiple vascular beds. • Empower clinicians to recognize VITT early, then effectively diagnose and treat the disorder to reduce morbidity and mortality. • Empower the public to be aware of VITT without causing undue alarm or overburdening the health-care system. • Inform on the existence of treatment. • Emphasize the real frequency of VITT and the overall benefit of vaccination. • VITT occurs after vaccination with non-replicant adenovirus vector-based vaccines (ChAdOx1, AstraZeneca/COVISHIELD; Ad26COV2.S, Janssen, Johnson & Johnson). • Symptoms suggestive of VITT: persistent and severe headache, occurring with a time delay following vaccination (discussed subsequently), with red flags, such as progressive worsening and resistance to symptomatic treatment; persistent and severe abdominal or back pain; focal neurological symptoms (including blurred or double vision); shortness of breath; persistent and severe chest pain; swelling and redness of a limb; or pallor and coldness of a limb. • Symptoms begin 5 or more days after vaccination, and typical presentations do not occur beyond 30 days except in some patients with isolated deep vein thromboses and pulmonary emboli, where the disease may remain subclinical for longer. • Patients may have multiple organ thrombosis, and in VITT patients with new symptoms or symptoms from different organs or systems, additional thromboses must be ruled out. • Platelet count and D-dimer are the most important screening laboratory tests. • Two scenarios to consider after the platelet count result: a. VITT UNLIKELY: Persistently normal platelet count (≥150 000/ µL). This does not rule out thrombosis due to other causes. Clinicians should work up alternative diagnoses, including non-VITT thrombosis. If no alternative diagnosis is found, patients should be encouraged to seek care immediately (and have a repeat platelet count) if symptoms worsen. Note: Especially in patients with a high platelet count before onset of VITT even a substantial decrease in platelet count may not cause platelet count numbers <150 000/µL, or it may take longer until the platelet count decreases to <150 000/µL. If symptoms clinically persist, a repeat blood cell count should be performed. • What to do if no D-dimer assay is available: a. Refer to the histogram of the automated particle counter; it will show a broadened curve not reaching baseline and not the typical smooth semi-logarithmic appearance. In addition, a blood film should be performed. In VITT, it will typically show multiple small platelet aggregates of 5-10 platelets. These small aggregates are not present in immune thrombocytopenic purpura patients ( Figure 1 ). • Standard laboratory testing. c. Consideration should be given to setting up regional referral centers that are capable of performing high sensitivity anti-PF4 antibody testing by validated ELISA techniques. Antibodies are stable in whole blood or serum shipped (at room temperature) to referral centers for at least 3 days. d. If no PF4 test is available, store serum sample at −20°C for later testing. Valid data on the prevalence of VITT in different ethnicities are urgently needed and stored samples can be used for this purpose. • Functional assays. a. Consideration should be given to setting up regional referral centers that are capable of performing functional assays of platelet activation to confirm the diagnosis of VITT and differentiate it from HIT. Blood samples for functional tests should be obtained before treatment with IVIG is started (IVIG inhibits functional assays). In centers where imaging is not readily available and there is a high clinical suspicion of VITT, appropriate empiric treatment should be initiated while imaging is arranged; therapeutic dose anticoagulation is justified by typical symptoms (e.g., persistent and severe headache with red flags, such as progressive worsening and resistance to symptomatic treatment, and no better explanation for the patient's thrombocytopenia and elevated D-dimer), and objective confirmation of CVST can be done after starting anticoagulation. In case of uncertainty of the diagnosis, the unlikely, possible, probable, definite criteria (Table 1) have been shown to be clinically easy to apply. and hematology teams should also be available to assist as needed. • Patients can deteriorate very quickly and treatment should not be delayed. • Patients with likely or confirmed VITT should ideally be treated in the inpatient setting, where they can be monitored for complications and disease progression until they considerably improve clinically. • Anticoagulation is the first pillar of treatment in VITT. • In very severe cases with platelet counts <30 000/µL and severe thrombosis, plasma exchange seems to improve outcome based on small case series. • Thrombocytopenia is not a contraindication to therapeutic dose anticoagulation in VITT. In fact, individuals with the lowest platelet counts may well be at highest risk of thrombosis. It is critical to begin IVIG in patients with VITT and profound thrombocytopenia, as raising the platelet count in concert with anticoagulation should mitigate bleeding risk. • The duration of anticoagulation is still unclear. In general, treatment must continue as long as the platelet count is low, and the D-dimer is elevated. The optimal duration is likely similar to non-VITT thrombosis (e.g., 3-6 months for venous thrombosis). Extended duration treatment can be challenging in areas with limited access to non-heparin anticoagulants. • In a small subset of VITT patients, platelet activating anti-PF4 antibodies persist for at least 5 months. Especially in patients who show persistently reduced platelet count numbers, D-dimer should be retested after stop of anticoagulation. An increase in D-dimer without other explanation indicates ongoing clotting activation and anticoagulation should be resumed. • Vitamin K antagonists must be avoided in acute VITT. They can cause protein C deficiency, and if the patient is already in a strongly hypercoagulable state (such as in VITT, HIT, malignancy, shock liver), they increase the risk for microcirculatory thrombosis. Vitamin K antagonists may be considered in the subacute period of VITT, that is, when the platelet count has normalized and remains stable for at least a week. • Aspirin must be avoided in acute VITT. Aspirin does not prevent or treat VITT. It does not prevent platelet activation in this condition and could increase the risk of bleeding. In patients with anti-platelet drug medication before onset of VITT, continuation should be discussed with the cardiologist balancing bleeding risk and underlying indication. c. We believe a second vaccination with the ChAdOx1 nCov-19 vaccine would be tolerated by most of these patients. An analogy would be HIT, in which re-exposure to heparin does not cause problems in most patients. Moreover, though there are reported cases of VITT associated with a second dose ChAdOx1 nCov-1, the vast majority have been found to be anti-PF4 antibody negative. VITT appears to be almost exclusively a "first dose problem." If VITT patients must be re-exposed to the ChAdOx1 nCov-19 vaccine, due to resource/availability/access issues, all efforts should be made to collect information on their clinical course. When robust evidence becomes available that the ChAdOx1 nCov-19 vaccine can be safely used a second time in VITT patients without adverse effects, this will make management of those patients in countries without ready access to non-adenoviral vector vaccines much easier. We strongly support full vaccination-with a complete series of-in all patients globally, including heterologous prime-boost vaccination ("mix and match" vaccines) in VITT patients if they have access to mRNA vaccines. We appreciate that global vaccine inequity is a major concern, and not all global citizens have the same access to vaccines, and to vaccine choice. The rise of highly transmissible COVID-19 variants is most concerning in areas with low vaccine coverage. Therefore, we do not support a strategy of incomplete vaccination in individuals with a history of VITT, as this leaves them and their fellow citizens who are immunocompromised and/or are unable to receive the vaccine for whatever reason, susceptible to COVID-19 complications. All efforts should be made to get these individuals fully vaccinated and optimally protected from COVID-19. • Though VITT is a rare vaccine-related adverse event, cases will certainly present in any setting where adenoviral vector COVID-19 vaccines are administered. This condition causes considerable morbidity and mortality, so clinicians must be prepared to effectively diagnose and treat it. Moreover, effective surveillance systems must be in place to facilitate case finding, and effective reporting structures must be in place to facilitate thorough data collection and rapid clinical support. Clinicians (and patients) should be encouraged to report cases, in the spirit of transparency and vaccine safety. • We recommend organized national/international help centers for VITT, providing round-the-clock support and telemedicine functionality. Selected relevant VITT references published after June 2021. Venous Thromboembolism and Mild Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination Online ahead of print Pathogenic Antibodies over Time in VITT Online ahead of print PF4 ANTIBOD IE S Laboratory testing for post ChAdOx1 nCOV-19 vaccination VITT: A challenge. Comment on: Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology Free PMC article. No abstract available. Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2 Free PMC artic Evaluation of laboratory assays for anti A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination Free PMC article. Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia Free PMC article. The use of IV immunoglobulin in the treatment of vaccine ChAdOx1 nCov-19 Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) Online ahead of print Online ahead of print Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia DS adenoviral vector-based vaccine, AstraZeneca, cerebral vein sinus thrombosis, platelets, SARS-CoV-2 vaccine, vaccine-induced immune thrombotic thrombocytopenia ACK N OWLED G M ENT The support of and valuable discussions with Dr MP has received honoraria for a lecture from Novartis, and has provided expert witness testimony relating to thrombotic disorders. SP has received honoraria for educational lectures, chairing and participation in advisory boards, or sponsorship for running courses from SOBI, Amgen, Alexion, Sanofi, CSL Behring, Novartis, Pharmacosmos, and Vifor Pharma, outside the submitted work. TEW has received lecture honoraria from Alexion and Instrumentation Laboratory, and royalties from Informa (Taylor & Francis); has provided consulting services to Aspen Canada, Aspen Global, Bayer, CSL Behring, Ergomed, and Octapharma; has received research funding from Instrumentation Laboratory; and has provided expert witness testimony relating to heparin-induced thrombocytopenia (HIT) and non-HIT thrombocytopenic and coagulopathic disorders Instrumentation Laboratory; non-financial support from Boehringer Ingelheim All authors wrote the manuscript and contributed their national and regional experience. All authors approved the final version of the manuscript Mike Makris 3